4 year BAA contract- FY26C1AP5-enhancing regulatory confidence in pediatric bioequivalence through validated TIM based mechanistic platforms and model integrated evidence
Active Definitive Contract Awarded Last action
- Contract number
- 75F40126C00101
- Awardee
-
University Of Strathclyde UEI WF55FB5QTR96
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $534,032
Award facts
- Opportunity
-
- FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Special Notice · FDABAA2600123 · Posted Nov 21, 2025
- Contract value 70% obligated
-
- $534,032.00 Current, with exercised options
- $760,505.00 Potential, with all options
- Completion date 1% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Great Britain, United Kingdom
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Food and Drug Administration awarded a $760,505 definitive contract to University of Strathclyde on November 2, 2026, for a four-year effort titled "Enhancing Regulatory Confidence in Pediatric Bioequivalence Through Validated TIM Based Mechanistic Platforms and Model Integrated Evidence," with performance completion targeted for November 1, 2030.
The originating solicitation is the FY26 FDA Broad Agency Announcement for Advanced Research and Development of Regulatory Science, a Special Notice issued under FAR 6.102(d)(2) and 35.016 seeking extramural research proposals to advance regulatory science across FDA-regulated domains. The announcement prioritizes modernizing development and evaluation of FDA-regulated products, strengthening post-market surveillance and labeling, and invigorating public health preparedness. The contract is firm fixed price with no set-aside applied. Place of performance is Great Britain, United Kingdom. The research area aligns with NAICS 541714 (Research and Development in Biotechnology) and PSC code AJ11 (General Science and Technology R&D Services).
Quick answers
Who was awarded contract 75F40126C00101?
75F40126C00101 was awarded to University Of Strathclyde by Food and Drug Administration (Department of Health and Human Services) on November 2, 2026.
How much is contract 75F40126C00101 worth?
The government has obligated $534,032 on 75F40126C00101. Its potential value, with all options, is $760,505.
Was contract 75F40126C00101 competed?
The extent of competition for 75F40126C00101 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award